Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Investor Presentation (January 2026)
36 slides from Cognition Therapeutics's investor presentation, January 2026
Slide 1: Zervimesine: a Once-daily Oral Therapeutic Advancing Toward Phase 3
Zervimesine: a Once-daily Oral Therapeutic Advancing Toward Phase 3 January 2026
Slide 2: Forward-looking Statements
Forward-looking Statements FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate t
Slide 3: Novel MoA Discovered Through Founder's Screening Assay
Novel MoA Discovered Through Founder’s Screening Assay Zervimesine Interrupts Binding of Toxic Oligomers • Phenotypic in vitro screen to select molecules that protect neurons from toxic oligomers • Screened 10,000 compounds, identified 5 unique chemical series Zervimesine • Zervimesine readily cross
Slide 4: Zervimesine (CT1812) – Lead Product Candidate
Zervimesine (CT1812) – Lead Product Candidate Extensive composition of matter IP on zervimesine Zervimesine • BBB-penetrant small molecule oligomer antagonist PrPc lilrb2 TMEM97 • Target: TMEM97 (sigma-2) receptor PGRMC1 • Oral, once-daily dosing, favorable safety data • Fast Track granted for Alzhe
Slide 5: Findings from Completed Studies Support Phase 3 Plans
Findings from Completed Studies Support Phase 3 Plans Patient Population Program Treatment Takeaways from completed studies period • Phase 2 SHINE Study: efficacy across Alzheimer’s disease MCI and Early Phase 2 COG0203 • START 18 months cognitive measures in mild-to-moderate Dementia with Lewy bodi
Slide 6: Regulatory Catalysts for Zervimesine
Regulatory Catalysts for Zervimesine Anticipate EMA feedback 1Q 2026 for Alzheimer’s disease Completed: AD End-of-Phase 2 Meeting Dementia with Lewy Bodies • Aligned with FDA on following: • FDA Type C meeting scheduled for January 2026 - Disease stage: mild-to-moderate AD • Will seek alignment with
Slide 7: Executive Program Summary
Executive Program Summary Compelling data with first-in-class candidate supports registrational plan • Consistent efficacy signals in Alzheimer’s, DLB and dry AMD - Effective in both mild & moderate Alzheimer’s disease - GA lesion growth reduced with zervimesine treatment • Well tolerated safety pro
Slide 8: Alzheimer's Disease
Alzheimer’s Disease 95% slowing of cognitive decline in lower-p-tau217 'SHINE' participants
Slide 9: AD and DLB: Two Diseases with Overlapping Pathology
AD and DLB: Two Diseases with Overlapping Pathology Primary treatment goal is to slow the progression of disease • Aβ: associated with Alzheimer’s pathogenesis Amyloid • α-synuclein: associated with Lewy body dementias beta (Aβ) • Co-pathology is common - Up to 80% of DLB patients have BOTH α-synucl
Slide 10: Phase 2 PoC in Mild-to-Moderate Alzheimer's Disease
Phase 2 PoC in Mild-to-Moderate Alzheimer’s Disease Well-executed, over-enrolled study, supports advancing clinical development Enrolled Population: Inclusion and Exclusion Treatment Period 6 months • PET- or biomarker-confirmed AD • AD diagnosis • Majority of participants were female • PET or CSF b
Slide 11: Up to 108% Slowing on Assessments in Lower p-Tau Population
Up to 108% Slowing on Assessments in Lower p-Tau Population Response of 100 and 300 mg dose groups are similar Cognition Function ADAS-Cog 11 ADAS-Cog 13 MMSE ADCS-ADL ADCS-CGIC median p-tau217 95% 103% 108% 68% 61% Endpoints measured 100/300mg zervimesine pooled vs placebo 11
Slide 12: Plasma p-Tau217: a Predictive Biomarker of Treatment Response
Plasma p-Tau217: a Predictive Biomarker of Treatment Response Plasma p-tau217 level correlates to degree of Alzheimer’s pathology • Individuals with lower levels of plasma p-tau217 at baseline have lower AD pathology. They show a greater response to amyloid- Increasing Levels of based therapies: Pla
Slide 13: Participants with Below Median p-Tau217 Experienced Profound Treatment Effect
Participants with Below Median p-Tau217 Experienced Profound Treatment Effect Successful end-of-Phase 2 meeting was based on these results ADAS-Cog 11* mITT population (n=150) Below median p-tau217 (n=69) Population selected for Phase 3 13 † Median plasma p-tau217 level is 1.0pg/mL at baseline
Slide 14: Consistent Treatment Impact in Participants with Lower p-Tau217 Across Baseline MMSE scores
Consistent Treatment Impact in Participants with Lower p-Tau217 Across Baseline MMSE scores Confirmed enrichment strategy and severity range at end-of-Phase 2 FDA meeting Zervimesine-treated Mild (MMSE 22-26) Participants Zervimesine-treated Moderate (MMSE 18-21) Participants 14
Slide 15: Phase 2 MCI and Early Alzheimer's Study
Phase 2 MCI and Early Alzheimer’s Study First study to allow approved mAbs as background therapy in combination with zervimesine Enrollment Treatment Period Program Assessments Criteria 18 months Objectives ‐ Ages 50-85 ‐ Safety Identify efficacy Zervimesine 200 mg signal(s) ‐ Diagnosis of MCI due
Slide 16: START Study Completed Enrollment 4Q 2025
START Study Completed Enrollment 4Q 2025 Trial duration: 18 months • Enrollment complete (n=545) - First participant enrolled February 2024 - Last participant enrolled in December 2025 • Topline results anticipated 2H 2027 • 15-20% of participants enrolled on lecanemab or donanemab • Sub-studies: MR
Slide 17: Dementia with Lewy Bodies (DLB)
Dementia with Lewy Bodies (DLB) Strong clinical signals across four major symptom domains in Phase 2 SHIMMER Study
Slide 18: Four Core Domains + Functional Impairment Drive DLB Burden
Four Core Domains + Functional Impairment Drive DLB Burden “A multifactorial disease with a buffet of symptoms” James E. Galvin, MD, MPH, Univ Miami Miller School of Medicine Behavior Cognition Fluctuations Movement Function Diminished Impaired memory Difficulty standing, Patient Hallucinations, abi
Slide 19: Complex Symptomology Requires Array of Assessments
Complex Symptomology Requires Array of Assessments Assessment tools measure a variety of symptoms Behavior Cognition Fluctuations Movement Function Cognitive Drug Clinician MDS-Unified PD ADCS-Activities Neuropsychiatric Research Assessment of Rating Scale Part III of Daily Inventory (NPI) (CDR) Sys
Slide 20: Phase 2 Study in Dementia with Lewy Bodies
Phase 2 Study in Dementia with Lewy Bodies Partially funded by $30M NIA grant (R01AG071643) Enrollment Treatment Period Program Assessments Criteria 6 months Objectives ‐ Age 50-85 ‐ Safety/tolerability Identify efficacy Zervimesine 300 mg 130 ‐ Behavior - NPI signal(s) ‐ DLB diagnosis participant
Slide 21: Up to 91% Percent Slowing on Assessments
Up to 91% Percent Slowing on Assessments Strong clinical signals across major DLB symptoms relative to placebo Behavior Cognition Fluctuations Movement Function Cognitive Drug Clinician MDS-Unified PD ADCS-Activities Neuropsychiatric Assessment Inventory (NPI) 86% Research (CDR) System 86% Assessmen
Slide 22: Zervimesine Showed Dramatic 86% Impact on Neuropsychiatric Measures
Zervimesine Showed Dramatic 86% Impact on Neuropsychiatric Measures NPI captures a variety of patient disturbances, including hallucinations, anxiety, and delusions NPI NPI favor Treatment with Zervimesine NPI Total Score (A-L) 86% Slowing LS Mean Difference from Placebo 95% CI Anxiety Delusions Hal
Slide 23: Because Participants Improved in Hallucinations, Delusions & Anxiety, Caregivers Reported Less Distress
Because Participants Improved in Hallucinations, Delusions & Anxiety, Caregivers Reported Less Distress Companion tool to measure caregiver distress based on neuropsychiatric symptoms NPI Distress NPI Distress favors Treatment with Zervimesine NPI Total Score (A-L) Caregiver Distress 114% Slowing LS
Slide 24: Fewer & Less Severe Fluctuations After 6 Months of Zervimesine Treatment
Fewer & Less Severe Fluctuations After 6 Months of Zervimesine Treatment CAF 91% slowing Clinician Assessment of Fluctuations Unpredictable lapses in attention or consciousness that can last minutes, hours or days 24 CAF: Clinician Assessment of Fluctuations
Slide 25: Maintenance of Self-care
Maintenance of Self-care 52% preservation in activities of daily living (ADL) measures ADCS-ADL 52% slowing Components of ADL Score Bathing Toileting Dressing Conversing Grooming Shopping Feeding Writing 25 ADCS-ADL: Activities of Daily Living
Slide 26: Maintenance of Motor Function
Maintenance of Motor Function 62% preservation in measures of movement MDS-UPDRS III 62% slowing Components of UPDRS III Balance Gait Speech Facial expression Rigidity Tremor 26 MDS-UPDRS III: Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III
Slide 27: DLB Expanded Access Program (COG1202)
DLB Expanded Access Program (COG1202) Funded by an anonymous donation from SHIMMER family Program Period Program Enrollment Criteria 12 months Objectives ‐ Age 50-85 Long-term safety 32 participants ‐ DLB diagnosis Open Zervimesine 100 mg enrolled at 8 Continued access to Label U.S. sites medica
Slide 28: Zervimesine Making an Impact for DLB Patients
Zervimesine Making an Impact for DLB Patients Participant from Phase 2 and EAP comments on his experience with zervimesine in SHIMMER For years, Susan would order for me at restaurants because I couldn't put In the mornings he would stand sentences together. Now, I can order on my there and forget w
Slide 29: MAGNIFY Topline Results
MAGNIFY Topline Results GA lesion growth slower with zervimesine treatment
Slide 30: MAGNIFY Trial in Dry AMD/GA
MAGNIFY Trial in Dry AMD/GA Zervimesine: oral drug development candidate for geographic atrophy Enrollment Treatment Period Program Assessments Criteria 24 months Objectives ‐ Age: ≥ 50 ‐ Change in GA lesion ‐ Identify efficacy ‐ Diagnosis of dry AMD area (FAF) signal(s) Zervimesine 200 mg Adults wi
Slide 31: Zervimesine Treatment Slowed GA Lesion Growth
Zervimesine Treatment Slowed GA Lesion Growth Effect size increases with exposure • 29% mean rate of change (slope) in GA lesion area vs placebo (p=0.0538) • Change in GA progression rate favored zervimesine vs placebo at each timepoint - 6-months: -11.79% - 12-months: -15.83% - 18-months: -28.19% (
Slide 32: Zervimesine Slowed GA Lesion Growth Rate (slope) and Area (observed)
Zervimesine Slowed GA Lesion Growth Rate (slope) and Area (observed) Slope Analysis1 Mean Area by Time1 Zervimesine Placebo Diff Growth rate 0.10 0.14 - 0.04 (mm2 / month) ± 0.015 ± 0.014 Annualized Growth rate (mm2 / year) 1.23 1.73 - 0.50 Percent Difference 29% from Placebo (P=0.054) 32 1) Data on
Slide 33: Consistent Safety Profile Across Completed Phase 2 Studies
Consistent Safety Profile Across Completed Phase 2 Studies Well tolerated in 271 participants with AD, DLB, dry AMD • Average age was ~75 years • Adverse events (AEs) were well balanced between treatment and placebo arms - Serious AEs occurred at comparable or higher rates in placebo- compared to ze
Slide 34: 3 Major Diseases Addressed with Once-Daily Oral Pill
3 Major Diseases Addressed with Once-Daily Oral Pill Collective Phase 2 results support advancing zervimesine (CT1812) to registrational studies Dementia with Alzheimer’s Disease Geographic Atrophy Lewy Bodies Marked slowing of progression Slowing of progression; robust Slowing of GA growth across m
Slide 35: Current Financial Position
Current Financial Position Cash runway into 2Q 2027 As of quarter ended September 30, 2025 Cash and cash equivalents $ 39.8 M Grant funding for zervimesine studies Preclinical through Phase 2 ~$171 M Approximate funding used ($135 M) Remaining grant funding $36 M 35
Slide 36: Thank You
Thank You Lisa Ricciardi President & CEO [email protected]
Cognition Therapeutics — Investor Presentation (January 2026) on 6ix